A Single Dose Five-way Cross-over Study to Establish an in Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets With 0.375 mg Pramipexole in Healthy Male Volunteers
Latest Information Update: 13 Oct 2014
At a glance
- Drugs Pramipexole (Primary)
- Indications Gilles de la Tourette's syndrome; Myoclonus; Parkinson's disease; Restless legs syndrome
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 13 Oct 2014 New trial record